18 clinical trials matched your search for Melanoma. You can click one of the clinical trials below for more information, or click the Search Again button to enter different search text.

Search Again
Condition Study Title Investigator
Melanoma Study of SD-101 in Patients with Metastatic Uveal Melanoma (Eye Cancer) with Liver Disease Alexander Wei, MD
Melanoma Study of ALKS 4230 in Patients with Previously Treated Advanced Melanoma Benjamin Izar, MD
Melanoma Study of DYP688 in Patients with Melanoma Shaheer Khan, DO
Melanoma Study of Fianlimab and Cemiplimab vs. Pembrolizumab in Patients with Resected High-Risk Melanoma Benjamin Izar, MD
Cancer A Study for Patients with Advanced Melanoma, Solid Tumors or Lymphoma Using Study Drug Pembrolizumab Nobuko Hijiya, MD
Cancer Identification of Targets for Cancer Treatment Andrea Califano, PhD
Uveal Melanoma A Prospective Natural History Study in Uveal Melanoma Shaheer Khan, DO
Cancer Study of IDE196 in Patients with Solid Tumors Shaheer Khan, DO
Cancer Study of IMC-F106C Alone and in Combination With Checkpoint Inhibitors in Participants with Advanced Cancers Benjamin Izar, MD
Cancer A Study of ASP9801 in Patients With Advanced Metastatic Solid Tumors Matthew Ingham, MD
Cancer Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Brian Henick, MD
Autoimmune Disorders Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Brian Henick, MD
Cancer Study of RP-3500 in Combination with PARP Inhibitor for Patients with Advanced Cancer Benjamin Herzberg, MD
Cancer Study of IDE397 in Patients with Advanced Solid Tumors Benjamin Herzberg, MD
Cancer Study of STK-012 Alone or in Combination with Pembrolizumab (KEYTRUDA) in Patients with Advanced Solid Tumors Benjamin Izar, MD
Cancer Study of E-602 Alone or in Combination with Libtayo (Cemiplimab) in Patients with Advanced Cancer Brian Henick, MD
Cancer Study of LNS8801 Alone or in Combination with Pembrolizumab in Patients with Advanced Cancer Brian Henick, MD
Cancer Study of XL092 Alone or in Combination with Anticancer Therapy in Patients with Unresectable orMetastatic Solid Tumors Karie D. Runcie, MD
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE